MedTrace Logo

Pharmacokinetics of AZD7295 Capsules

NCT01097408 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-08-09

No results posted yet for this study

Summary

This is a pharmacokinetics (PK) and safety study of AZD7295 in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

AZD7295

Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.

DRUG

Placebo comparator

Placebo capsules

Sponsors & Collaborators

  • Arrow Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jo Collier, Mb ChB · Quotient Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-05-31
Completion
2010-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01097408 on ClinicalTrials.gov